Nature Medicine Response to Reviewers: How to Write a Rebuttal That Wins (2026)

State the exact page and line number for each manuscript revision, and reference the specific figure, table, supplementary file, or reporting checklist you changed. This is the single most-cited rebuttal failure at Nature Medicine and across the Nature Portfolio.

A reviewer who has to hunt for your reanalysis reads it as evasion. One who can click straight to Table 2 and the Methods on page 15, lines 4 to 12, finishes faster and re-reviews more favorably.

Never write "we have addressed this in the manuscript" without a location. Use the line numbers from the revised file, not the original, and note when a change lives in a Supplementary figure or in a CONSORT, STROBE, TRIPOD, or STARD checklist item rather than the main text.

The reviewers see your tone across every comment, and a real analysis problem cannot be solved with rhetoric. Calibrate.

The pattern that works at Nature Medicine: concede where the reviewer is right, run the data or the reanalysis, point to the exact change and the reporting checklist, and push back only on a request that is genuinely out of scope, with a reason and an alternative.

Nature Medicine is editor-led: a professional handling editor, not an academic editor, owns the decision and decides what a revision must demonstrate.

The journal desk-screens heavily, so a paper that reaches review has already cleared a steep clinical-translation filter. Nature Portfolio policy says papers selected for formal review are typically sent to two or three reviewers, with more reviewers possible when special advice is needed, including statistics or a particular technique.

That statistical scrutiny is the feature most authors underestimate. When a reviewer flags the analysis, your numbers need a real answer, not a wording change in place of a reanalysis.

The journal's reporting-standards gate is its other defining feature. Randomized trials must conform to CONSORT 2025 and include the completed checklist, and Nature Medicine states that reports not conforming to CONSORT may need to be revised before formal review.

Observational studies use STROBE, prediction models use TRIPOD, and diagnostic-accuracy studies use STARD. A reporting-checklist gap is not a soft suggestion at Nature Medicine; it can hold your manuscript before reviewers ever read the science.

In your rebuttal, treat each reporting comment as a concrete fix: complete the checklist, add the missing flow diagram or item, and cite the page and line.

Nature Medicine also runs transparent peer review on an opt-in basis. At the completion of peer review, before the paper is accepted, authors choose whether to publish the reviewer comments and their author rebuttal letters alongside the article.

Reviewer comments to editors and editor-author correspondence stay confidential, and reviewers may sign their reports if they choose.

The practical consequence: write your response to reviewers as a document that future clinicians, competitors, and grant panels may read. A rebuttal that concedes cleanly and shows new clinical data becomes evidence of rigor; one that is evasive or dismissive becomes part of a published record.

A major revision at Nature Medicine carries a specific meaning. It typically requires new clinical data, additional cohorts, validation experiments, or substantial reanalysis, and the handling editor and reviewers judge whether the new evidence resolves the translational or statistical concern. So the bar is real work, documented precisely, reported to standard, written for a possibly public audience.

How this compares to the rest of the field matters for calibration. A response to reviewers at the New England Journal of Medicine or The Lancet faces a clinical-trials desk built around its own statistical and ethics review, while at JAMA the biostatistical filter is famously heavy.

Nature Medicine sits at the intersection of the basic-science Nature Portfolio and the clinical journals. It wants translational depth and mechanistic novelty, but it also runs CONSORT-class reporting and statistical scrutiny like a clinical journal.

That dual identity is the thing authors miss. A rebuttal written only for the mechanism reviewer, with a hand-wave for the statistics and a missing CONSORT checklist, reads as a basic-science response submitted to a clinical journal.

In our pre-submission review work with Nature Medicine submissions, the rebuttals that stall in a second revision round share a small set of recurring weaknesses.

These are the same ones reviewers flag at re-review, and because Nature Medicine can publish the exchange under transparent peer review if authors opt in, they also risk becoming part of the permanent record.

In our analysis of Nature Medicine rebuttals, each weakness below maps to a specific, named failure pattern in the editorial culture, and each is testable against your own draft response before you upload it.

Wording fixes where a statistical concern required reanalysis. The most common and most expensive pattern in our Nature Medicine pre-submission reviews is a rebuttal that answers a request to correct the statistical analysis with a sentence added to the Methods.

A major revision at Nature Medicine usually means new data or a rerun model, not a clarification. When a reviewer questions a multiple-comparisons correction or a missing power calculation, adding a hedge to the text does not move the decision; rerunning the analysis and reporting the adjusted p-value does.

A murine result oversold as human-ready, with no new cohort. Nature Medicine wants the translational bridge convincing, so a clinical reviewer who flags weak human relevance is asking for evidence, not softer language.

In our pre-submission review work with Nature Medicine manuscripts, the rebuttals that fail this comment add a caveat to the Discussion instead of adding a validation cohort or patient-sample analysis. The fix that clears the comment is a new control or validation experiment that tests the claim in human-relevant material, cited to a new figure, page, and line.

A CONSORT, STROBE, or STARD checklist gap left for the editor. Because Nature Medicine gates reporting standards before formal review, a reporting-checklist gap is a fast, avoidable cause of delay. In our Nature Medicine pre-submission reviews, manuscripts reporting a trial or observational study routinely arrive with an incomplete reporting checklist or a missing participant-flow diagram. The rebuttal that resolves it completes the relevant checklist, adds the missing figure or item, and maps each checklist line to a manuscript page and line, rather than promising to "ensure compliance."

Inconsistent answers across reviewers. A rebuttal that frames the same sample size or endpoint concern one way for Reviewer 1 and another way for Reviewer 3 reads as evasive.

In our Nature Medicine pre-submission reviews we routinely find a cohort-size or methods concern raised by two reviewers and answered with two different justifications. Reconcile every overlapping comment to a single, consistent answer before submission.

Run the new data, fix the reporting checklist, satisfy the statistician, and reconcile across reviewers. That four-part discipline is what separates a Nature Medicine rebuttal that clears one revision round from one that stalls into a second or third. Check your Nature Medicine point-by-point response for these patterns before you submit.

Source: Manusights pre-submission reviews of Nature Medicine-targeted resubmissions, 2025 cohort.

Authors consistently underestimate the new-data and reanalysis effort and overestimate the writing effort. This breakdown is about workload, not the journal's decision clock; for the end-to-end decision schedule, see the Nature Medicine review time guide.

Source: Manusights pre-submission reviews of Nature Medicine resubmissions, 2025 cohort, last updated June 6, 2026.

A major-revision invitation at Nature Medicine is not a soft acceptance. The revised manuscript and your point-by-point response can go back to reviewers, and the paper can still end in rejection after re-review if the new clinical data or reanalysis do not resolve the core concern.

Even among papers that reach review, the bar at resubmission stays high. Most rejections at this stage trace to one cause: the author answered a request for new data or reanalysis with wording changes.

The second most common is a reporting-standard gap, a missing CONSORT or STROBE item, that the editor cannot wave through.

Think twice before you resubmit if any of these are true.

The response uses generic "we have addressed this" language with no page or line numbers. A reviewer asked for a reanalysis and you answered with text. A clinical reviewer asked for human validation and you only softened the claim.

Also pause if the reporting checklist is still incomplete or the same comment from two reviewers got two different answers. Fixing these before resubmission is what keeps a second round from becoming a rejection, sometimes with a transfer offer to a Nature Portfolio specialty journal where the reports can carry forward.

The official guidelines tell you to submit a point-by-point response and to include the reporting checklists.

They do not tell you how an editor-led Nature Medicine revision feels in practice: a reporting-checklist gap can stall the paper before formal review, a major revision usually means new clinical or translational data rather than clarifications, and the letter may be published under transparent peer review if you opt in.

Those facts change how you write every reply. The patterns above come from our pre-submission reviews of Nature Medicine rebuttals, and they are testable against your own draft today, not theoretical concerns.

• Manusights pre-submission reviews of Nature Medicine-targeted manuscripts (2025 cohort)